- Home
- CMBM vs KYNB Comparison
CMBM vs KYNB Comparison
Compare CMBM & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | KYNB |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 31.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMBM | KYNB |
|---|---|---|
| Price | $1.19 | $8.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 189.8K | 30.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $220,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $7.11 |
| 52 Week High | $6.80 | $9.58 |
Technical Indicators
Market Signals| Indicator | CMBM | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 42.18 |
| Support Level | $1.13 | $7.37 |
| Resistance Level | $1.81 | $8.84 |
| Average True Range (ATR) | 0.09 | 0.60 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 18.85 | 25.53 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.